STAT· @statnews · X·· 27 天前精选AI 评分62
AI 导读
GSK的乙肝药物获得FDA批准,将以Hibsago为商品名上市。该批准覆盖部分慢性乙肝感染的成人患者,慢性乙肝是肝硬化和肝癌的主要病因之一,每年导致100万人死亡。
推荐理由
GSK乙肝新药获FDA批准,读者可了解其商品名与适用人群范围。
正文
GSK has won FDA approval for its hepatitis B drug, which will be marketed as Hibsago.
The approval for the drug covers select adults with chronic hep B infections, a leading cause of liver cancer and cirrhosis and which kill 1 million people a year. https://trib.al/uEcNtm7
来源:STAT · x.com